Company profile: Visby Medical
1.1 - Company Overview
Company description
- Provider of instrument-free PCR diagnostic tests for infectious disease detection, including the single-use Sexual Health Test that detects Chlamydia, Gonorrhea, and Trichomoniasis from self-collected vaginal swabs in under 30 minutes, and the Respiratory Health Test that detects and differentiates COVID-19, Influenza A, and Influenza B via nasopharyngeal swabs in under 30 minutes.
Products and services
- PCR Diagnostic Test Development: Engineers PCR-based diagnostics for infectious disease detection, producing polymerase chain reaction tests expressly developed to detect pathogens causing infectious diseases
- Visby Medical Respiratory Health Test: Produces an instrument-free PCR assay that detects and differentiates COVID-19, Influenza A, and Influenza B in under 30 minutes using nasopharyngeal swabs
- Visby Medical Sexual Health Test: Delivers a single-use, instrument-free PCR test detecting Chlamydia, Gonorrhea, and Trichomoniasis in under 30 minutes using self-collected vaginal swabs.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Visby Medical
DelSiTech
HQ: Finland
Website
- Description: Provider of biodegradable silica-based controlled-release drug delivery technologies and drug development services, focusing on parenteral and local administration. Offers Silica Matrix platform for small molecules, biopharmaceuticals, and viral vectors; long-acting injectables, ocular drug delivery, and supergeneric/505(b)(2) products such as DST1308 and DST2105.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DelSiTech company profile →
Anacor Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics based on a boron chemistry platform, focused on developing topical treatments for fungal, bacterial, and inflammatory diseases, including its primary product candidate AN2690, a novel topical antifungal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anacor Pharmaceuticals company profile →
Microgen Bioproducts
HQ: United Kingdom
Website
- Description: Provider of diagnostic products for clinical, food, and environmental testing, with a portfolio for clinical laboratories including microbiology diagnostics; engages in the development, manufacture, distribution, and marketing of products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microgen Bioproducts company profile →
Alverix
HQ: United States
Website
- Description: Provider of low-cost handheld reader devices with laboratory-grade accuracy and precision; partnering with diagnostic and OEM manufacturers to increase test accuracy, improve portability of existing tests, and develop new assays for use in physician offices and laboratory outreach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alverix company profile →
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Visby Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Visby Medical
2.2 - Growth funds investing in similar companies to Visby Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Visby Medical
4.2 - Public trading comparable groups for Visby Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →